Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases

Haematologica

Volumn 102, Issue 11, 2017, Pages 1823-1832

  Arnold, Staci D ^a   Brazauskas, Ruta ^b   He, Naya ^b   Li, Yimei ^c   Aplenc, Richard ^c   Jin, Zhezhen ^an   Hall, Matt ^d   Atsuta, Yoshiko ^e,f   Dalal, Jignesh ^g   Hahn, Theresa ^h   Khera, Nandita ⁱ   Bonfim, Carmem ^j   Majhail, Navneet S ^k   Diaz, Miguel Angel ^l   Freytes, Cesar O ^m   Wood, William A ⁿ   Savani, Bipin N ^o   Kamble, Rammurti T ^p   Parsons, Susan ^q   Ahmed, Ibrahim ^g   Sullivan, Keith ^r   Beattie, Sara ^s   Dandoy, Christopher ^t   Munker, Reinhold ^u   Marino, Susana ^v   Bitan, Menachem ^w   Abdel Azim, Hisham ^x   Aljurf, Mahmoud ^y   Olsson, Richard F ^z,aa   Joshi, Sarita ^ab   Buchbinder, Dave ^ac   Eckrich, Michael J ^ad   Hashmi, Shahrukh ^y,ae   Lazarus, Hillard ^af   Marks, David I ^ag   Steinberg, Amir ^ah   Saad, Ayman ^ai   Gergis, Usama ^aj   Krishnamurti, Lakshmanan ^a   Abraham, Allistair ^ak   Rangarajan, Hemalatha G ^ab   Walters, Mark ^al   Lipscomb, Joseph ^am   Saber, Wael ^b   Satwani, Prakash ^d   more..

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Department of Medicine   (United States)

^e JAPANESE DATA CENTER FOR HEMATOPOIETIC CELL TRANSPLANTATION   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^k TAUSSIG CANCER INSTITUTE   (United States)

^l HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^m TEXAS TRANSPLANT INSTITUTE   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^o VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^p CENTER FOR CELL AND GENE THERAPY   (United States)

^q TUFTS MEDICAL CENTER   (United States)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY OF OTTAWA   (Canada)

^t CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^u LOUISIANA STATE UNIVERSITY   (United States)

^v UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^w TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^x UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^y KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^z KAROLINSKA INSTITUTE   (Sweden)

^aa UPPSALA UNIVERSITY   (Sweden)

^ab OHIO STATE UNIVERSITY   (United States)

^ac CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^ad Atrium Health Levine Children's Hospital   (United States)

^ae MAYO CLINIC   (United States)

^af UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^ag UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^ah MOUNT SINAI HOSPITAL   (United States)

^ai Heerskink School of Medicine   (United States)

^aj NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^ak CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^al CHILDREN S HOSPITAL OAKLAND   (United States)

^am EMORY UNIVERSITY   (United States)

^an Department of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LENGTH OF STAY; MALE; MORTALITY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK; SICKLE CELL ANEMIA; UNITED STATES; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL DECISION MAKING; COMORBIDITY; DONOR; FACTUAL DATABASE; GRAFT VERSUS HOST REACTION; INCIDENCE; INFANT; NEWBORN; PATIENT ATTITUDE; PRESCHOOL CHILD; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANEMIA, SICKLE CELL; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CLINICAL DECISION-MAKING; COMORBIDITY; DATABASES, FACTUAL; FEMALE; GRAFT VS HOST DISEASE; HEALTH CARE COSTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MORTALITY; PATIENT ACCEPTANCE OF HEALTH CARE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85032664905     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.169581     Document Type: Article

References (33)

1. Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012; 59(2): 377-385.
2. Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013; 2013: 370-376.
3. Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016; 22(2): 207-211.
4. Mikles B, Bhatia M, Oyeku SO, Green NS. Hematology provider perspectives on hematopoietic stem cell transplantation for pediatric sickle cell disease. Blood. 2012; 120(21): 4276-4276.
5. Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediat Blood Cancer. 2015; 62(11): 1956-1961.
6. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009; 84(6): 323-327.
7. Jiang HJ, Weiss AJ, Barrett ML, Sheng M. Characteristics of hospital stays for superutilizers by payer, 2012: Statistical Brief #190. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD) 2015.
8. Arnold SD, Jin Z, Sands S, Bhatia M, Kung AL, Satwani P. Allogeneic hematopoietic cell transplantation for children with sickle cell disease is beneficial and cost-effective: a single-center analysis. Biol Blood Marrow Transplant. 2015; 21(7): 1258-1265.
9. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children’s hospitals. JAMA. 2011; 305(7): 682-690.
10. Li Y, Hall M, Fisher BT, et al. Merging Children’s Oncology Group data with an external administrative database using indirect patient identifiers: a report from the Children’s Oncology Group. PLoS One. 2015; 10(11): e0143480.
11. Aplenc R, Fisher BT, Huang YS, et al. Merging of the National Cancer Institutefunded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children’s Oncology Group. Pharmacoepidemiol Drug Saf. 2012; 21(Suppl 2): 37-43.
12. Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007; 40(9): 813-821.
13. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2016; 129(11): 1548-1556.
14. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014; 99(5): 811-820.
15. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000; 18(1): 64-71.
16. Svahn BM, Remberger M, Alvin O, Karlsson H, Ringden O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2012; 47(5): 706-715.
17. Shenoy S, Eapen M, Wu J, et al. A multicenter phase II trial of unrelated donor reduced intensity bone marrow transplantation for children with severe sickle cell disease (SCURT): results of the blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) study. Blood. 2015; 126(23): 619-619.
18. Meier ER, Dioguardi JV, Kamani N. Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia. Pediatr Blood Cancer. 2015; 62(7): 1277-1284.
19. Bhatia M, Sheth S. Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med. 2015; 6: 229-238.
20. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009; 15(5): 564-573.
21. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014; 124(7): 3121-3128.
22. Wagner JE, Brunstein CG, Boitano AE, et al. Phase I/II trial of StemRegenin-1 Expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2015; 18(1): 144-155.
23. Wagner JE, Jr., Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014; 371(18): 1685-1694.
24. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012; 120(22): 4285-4291.
25. Carroll CP, Haywood C, Jr., Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med. 2011; 6(5): 248-255.
26. Bhatia M, Kolva E, Cimini L, et al. Healthrelated quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015; 21(4): 666-672.
27. Kelly MJ, Pennarola BW, Rodday AM, Parsons SK, Journeys to Recovery Study HCS. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer. 2012; 59(4): 725-731.
28. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016; 387(10019): 661-670.
29. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013; 132(4): 677-683.
30. Bernaudin F, Robin M, Ferry C, et al. Related myeloablative stem cell transplantation (SCT) to cure sickle cell anemia (SCA): update of French results. Blood. 2010: 116(21): 3518.
31. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005; 23(27): 6596-6606.
32. Jaime-Pérez JC, Heredia-Salazar AC, Cantú-Rodríguez OG, et al. Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico. Oncologist. 2015; 20(4): 386-392.
33. Sharma SK, Choudhary D, Gupta N, et al. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014; 6(1): e2014046.